BioStem Technologies Begins Construction Of New Laboratory Facility

(Click here for details)
BioStem Technologies, Inc - New Laboratory Facility Rendering

OAKLAND PARK, FL--(Marketwired - July 13, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) (the "Company" or "BioStem") announced today the commencement of construction of the Company's new pharmaceutical grade laboratory facility. Biostem's pharmaceutical and nutraceutical operations have expanded rapidly since the change of control in late 2014, and the Company has revised its original plans for the facility to include less office space and more 'small batch' manufacturing rooms and general laboratory space.

The new, state-of-the-art facility will house multiple general labs, clean rooms, and small batch manufacturing rooms to support production and development of pharmaceutical, nutraceutical and cell based products. The facility will also be open for industrial and educational tours as a way of furthering BioStem's integrated mission of science, education and exhibition of the vast array of opportunities and benefits that are available to mankind through stem cell and nutritional products.

"This facility will give our scientists and researchers the laboratory resources they need to rapidly develop new products. We're looking forward to streamlining our developmentment and manufacturing processes, and to having the ability to test efficacy of these compounds in-house" said Andrew Van Vurst, COO of BioStem Technologies.

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.